Self-Assembled Nanoparticles as Cancer Therapeutic Agents

Most therapeutic agents for cancer are currently suffering from the shortcomings of poor solubility, severe side effects, and multidrug resistance. Supramolecular self-assembly (SSA) in nanomedicines is a promising way to overcome these obstacles due to the distinguished properties of noncovalent self-assembly such as functional diversity, easy stimulus-response, high biocompatibility, and biodegradability. Moreover, it is more potential to transform them from lab to clinic. In this review, based on lots of state-of-the-art studies, a summary is presented about the recent advances in SSA for cancer treatment, with the introduction of noncovalent driving forces, classifications, design, and applications of multifunctional self-assembled nanoparticles (SANPs). Finally, the prospects of SANPs on both developing drugs and clinical transformation are discussed.

Automated summary

Supramolecular self-assembly in nanomedicines shows promise in overcoming the limitations of current cancer therapeutic agents, with the potential to transition from the lab to clinical settings. The review summarizes recent advances in this area, covering noncovalent driving forces, classifications, design, and applications of multifunctional self-assembled nanoparticles.